{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:45:03Z","timestamp":1792449903993,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012357","name":"LifeArc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014331","name":"Motor Neurone Disease Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011776","name":"MND Scotland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011776","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.molmed.2025.03.008","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T16:18:27Z","timestamp":1744647507000},"page":"1077-1088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Phosphoglycerate kinase 1 as a therapeutic target in neurological disease"],"prefix":"10.1016","volume":"31","author":[{"given":"Harriet","family":"McHale-Owen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiterie M.E.","family":"Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Chaytow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0306-5577","authenticated-orcid":false,"given":"Thomas H.","family":"Gillingwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2025.03.008_bb0005","doi-asserted-by":"crossref","first-page":"7653","DOI":"10.1002\/jcp.29682","article-title":"Glucose, glycolysis, and neurodegenerative diseases","volume":"235","author":"Tang","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.31083\/j.fbl2903092","article-title":"Phosphoglycerate kinase 1: an effective therapeutic target in cancer","volume":"29","author":"Qiu","year":"2024","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.molmed.2025.03.008_bb0015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40478-021-01224-4","article-title":"Reappraisal of metabolic dysfunction in neurodegeneration: focus on mitochondrial function and calcium signaling","volume":"9","author":"Jadiya","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.molmed.2025.03.008_bb0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brainresbull.2017.03.009","article-title":"Metabolic dysfunction in Parkinson\u2019s disease: bioenergetics, redox homeostasis and central carbon metabolism","volume":"133","author":"Anandhan","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.molmed.2025.03.008_bb0025","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.neurobiolaging.2013.11.025","article-title":"Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis","volume":"35","author":"Allen","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.molmed.2025.03.008_bb0030","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1007\/s12035-015-9165-7","article-title":"Metabolomic analysis reveals increased aerobic glycolysis and amino acid deficit in a cellular model of amyotrophic lateral sclerosis","volume":"53","author":"Valbuena","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12964-023-01256-4","article-title":"Regulation of phosphoglycerate kinase 1 and its critical role in cancer","volume":"21","author":"Zhang","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.molmed.2025.03.008_bb0040","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/j.1460-2075.1982.tb01366.x","article-title":"Sequence and structure of yeast phosphoglycerate kinase","volume":"1","author":"Watson","year":"1982","journal-title":"EMBO J."},{"key":"10.1016\/j.molmed.2025.03.008_bb0045","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1093\/nar\/gkn212","article-title":"Molecular basis for the lack of enantioselectivity of human 3-phosphoglycerate kinase","volume":"36","author":"Gondeau","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molmed.2025.03.008_bb0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF02738169","article-title":"Folding funnels and conformational transitions via hinge-bending motions","volume":"31","author":"Kumar","year":"1999","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.molmed.2025.03.008_bb0055","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.febslet.2013.05.012","article-title":"Conformational dynamics in phosphoglycerate kinase, an open and shut case?","volume":"587","author":"Bowler","year":"2013","journal-title":"FEBS Lett."},{"key":"10.1016\/j.molmed.2025.03.008_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.801985","article-title":"Biological functions and regulatory mechanisms of hypoxia-inducible factor-1alpha in ischemic stroke","volume":"12","author":"He","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fphys.2015.00137","article-title":"Novel perspectives on the PHD-HIF oxygen sensing pathway in cardioprotection mediated by IPC and RIPC","volume":"6","author":"Martin-Puig","year":"2015","journal-title":"Front. Physiol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0070","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1538\/expanim.23-0019","article-title":"Phosphoglycerate kinase (PGK) 1 succinylation modulates epileptic seizures and the blood-brain barrier","volume":"72","author":"Luo","year":"2023","journal-title":"Exp. Anim."},{"key":"10.1016\/j.molmed.2025.03.008_bb0075","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1038\/s41467-024-51232-w","article-title":"Hypoxia-induced downregulation of PGK1 crotonylation promotes tumorigenesis by coordinating glycolysis and the TCA cycle","volume":"15","author":"Guo","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.03.008_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2023.148724","article-title":"Upregulation of mitochondrial PGK1 by ROS-TBC1D15 pathway promotes neuronal death after oxygen-glucose deprivation\/reoxygenation injury","volume":"1825","author":"Chen","year":"2024","journal-title":"Brain Res."},{"key":"10.1016\/j.molmed.2025.03.008_bb0085","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.molcel.2018.09.007","article-title":"Nuclear PGK1 alleviates ADP-dependent inhibition of CDC7 to promote DNA replication","volume":"72","author":"Li","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molmed.2025.03.008_bb0090","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s42003-023-05223-0","article-title":"Extracellular Pgk1 interacts neural membrane protein enolase-2 to improve the neurite outgrowth of motor neurons","volume":"6","author":"Fu","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114115","article-title":"A novel inhibitor of PGK1 suppresses the aerobic glycolysis and proliferation of hepatocellular carcinoma","volume":"158","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.molmed.2025.03.008_bb0100","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-018-0622-0","article-title":"A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling","volume":"562","author":"Bollong","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2025.03.008_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114437","article-title":"PGK1 modulates balance between pro- and anti-inflammatory cytokines by interacting with ITI-H4","volume":"161","author":"Park","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.molmed.2025.03.008_bb0110","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/35048596","article-title":"Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase","volume":"408","author":"Lay","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2025.03.008_bb0115","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/s41467-024-45443-4","article-title":"Phosphoglycerate kinase 1 acts as a cargo adaptor to promote EGFR transport to the lysosome","volume":"15","author":"Chu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.03.008_bb0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13024-023-00634-3","article-title":"Axonal energy metabolism, and the effects in aging and neurodegenerative diseases","volume":"18","author":"Yang","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.molmed.2025.03.008_bb0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fnins.2020.00213","article-title":"Neurodegenerative diseases \u2013 is metabolic deficiency the root cause?","volume":"14","author":"Muddapu","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.molmed.2025.03.008_bb0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson\u2019s disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2025.03.008_bb0135","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/brain\/awu159","article-title":"Grey matter hypometabolism and atrophy in Parkinson\u2019s disease with cognitive impairment: a two-step process","volume":"137","author":"Gonzalez-Redondo","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.molmed.2025.03.008_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fncom.2024.1328699","article-title":"Random forest analysis of midbrain hypometabolism using [18F]-FDG PET identifies Parkinson\u2019s disease at the subject-level","volume":"18","author":"Ruppert-Junck","year":"2024","journal-title":"Front. Comput. Neurosci."},{"key":"10.1016\/j.molmed.2025.03.008_bb0145","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.cub.2015.07.050","article-title":"Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons","volume":"25","author":"Pacelli","year":"2015","journal-title":"Curr. Biol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0150","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn6016","article-title":"Phosphoglycerate kinase is a central leverage point in Parkinson\u2019s disease-driven neuronal metabolic deficits","volume":"10","author":"Kokotos","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2025.03.008_bb0155","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/mdc3.13992","article-title":"X-linked levodopa-responsive parkinsonism-epilepsy syndrome: a novel PGK1 mutation and literature review","volume":"11","author":"Guimaraes","year":"2024","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.molmed.2025.03.008_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104816","article-title":"Novel Drosophila model for parkinsonism by targeting phosphoglycerate kinase","volume":"139","author":"Shimizu","year":"2020","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.molmed.2025.03.008_bb0165","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1172\/JCI129987","article-title":"Enhancing glycolysis attenuates Parkinson\u2019s disease progression in models and clinical databases","volume":"129","author":"Cai","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.03.008_bb0170","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cell.2013.12.042","article-title":"Activity-driven local ATP synthesis is required for synaptic function","volume":"156","author":"Rangaraju","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2025.03.008_bb0175","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/mds.28712","article-title":"Exposure to phosphoglycerate kinase 1 activators and incidence of Parkinson\u2019s disease","volume":"36","author":"Gros","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.molmed.2025.03.008_bb0180","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamaneurol.2020.5157","article-title":"Association of glycolysis-enhancing alpha-1 blockers with risk of developing Parkinson disease","volume":"78","author":"Simmering","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0185","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145112","article-title":"Parkinson disease among patients treated for benign prostatic hyperplasia with alpha1 adrenergic receptor antagonists","volume":"131","author":"Sasane","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.03.008_bb0190","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1002\/mds.29184","article-title":"Use of glycolysis-enhancing drugs and risk of Parkinson\u2019s disease","volume":"37","author":"Simmering","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.molmed.2025.03.008_bb0195","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3233\/JPD-240104","article-title":"Exposure to glycolysis-enhancing drugs and risk of Parkinson\u2019s disease: a meta-analysis","volume":"14","author":"Ribeiro","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.molmed.2025.03.008_bb0200","article-title":"(2024) Reprint of: The impact of alpha-1-adrenergic receptor antagonists on the progression of Parkinson disease","volume":"64","author":"Opheim","year":"2003","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.molmed.2025.03.008_bb0205","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41531-023-00477-1","article-title":"Glycolysis-enhancing alpha(1)-adrenergic antagonists modify cognitive symptoms related to Parkinson\u2019s disease","volume":"9","author":"Weber","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.molmed.2025.03.008_bb0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2021.11.022","article-title":"A pilot to assess target engagement of terazosin in Parkinson\u2019s disease","volume":"94","author":"Schultz","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.molmed.2025.03.008_bb0215","doi-asserted-by":"crossref","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.molmed.2025.03.008_bb0220","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00401-018-1835-x","article-title":"Energy metabolism in ALS: an underappreciated opportunity?","volume":"135","author":"Vandoorne","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0225","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrneurol.2014.184","article-title":"The phenotypic variability of amyotrophic lateral sclerosis","volume":"10","author":"Swinnen","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0230","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/hmg\/ddm367","article-title":"Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy","volume":"17","author":"Murray","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2025.03.008_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006744","article-title":"Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy","volume":"13","author":"Boyd","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.molmed.2025.03.008_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104202","article-title":"Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis","volume":"83","author":"Chaytow","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.molmed.2025.03.008_bb0245","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.3390\/ijms22115887","article-title":"Glucose metabolic dysfunction in neurodegenerative diseases-new mechanistic insights and the potential of hypoxia as a prospective therapy targeting metabolic reprogramming","volume":"22","author":"Han","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2025.03.008_bb0250","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fnmol.2019.00159","article-title":"Metabolic profiling reveals biochemical pathways and potential biomarkers of spinocerebellar ataxia 3","volume":"12","author":"Yang","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.molmed.2025.03.008_bb0255","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1007\/s13346-023-01498-2","article-title":"Efficiency of PGK1 proteins delivered to the brain via a liposomal system through intranasal route administration for the treatment of spinocerebellar ataxia type 3","volume":"14","author":"Chen","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.molmed.2025.03.008_bb0260","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1007\/s12035-023-03389-6","article-title":"Activation of Pgk1 results in reduced protein aggregation in diverse neurodegenerative conditions","volume":"60","author":"Chen","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0265","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209570","article-title":"Association of terazosin, doxazosin, or alfuzosin use and risk of dementia with Lewy bodies in men","volume":"103","author":"Hart","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2025.03.008_bb0270","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuroscience.2023.05.019","article-title":"Downregulated phosphoglycerate kinase 1 attenuates cerebral ischemia-reperfusion injury by reversing neuroinflammation and oxidative stress through the nuclear factor erythroid 2 related factor 2\/ARE pathway","volume":"524","author":"Liu","year":"2023","journal-title":"Neuroscience"},{"key":"10.1016\/j.molmed.2025.03.008_bb0275","doi-asserted-by":"crossref","first-page":"13388","DOI":"10.18632\/aging.103443","article-title":"PGK1 inhibitor CBR-470-1 protects neuronal cells from MPP+","volume":"12","author":"Zheng","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.molmed.2025.03.008_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113435","article-title":"Evodiamine prevents traumatic brain injury through inhibiting oxidative stress via PGK1\/NRF2 pathway","volume":"153","author":"Xu","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.molmed.2025.03.008_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2024.149116","article-title":"Diallyl trisulfide regulates PGK1\/Nrf2 expression and reduces inflammation to alleviate neurological damage in mice after traumatic brain injury","volume":"1843","author":"Chen","year":"2024","journal-title":"Brain Res."},{"key":"10.1016\/j.molmed.2025.03.008_bb0290","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12017-023-08736-3","article-title":"The role of PGK1 in promoting ischemia\/reperfusion injury-induced microglial M1 polarization and inflammation by regulating glycolysis","volume":"25","author":"Cao","year":"2023","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.molmed.2025.03.008_bb0295","doi-asserted-by":"crossref","first-page":"21262","DOI":"10.1074\/jbc.271.35.21262","article-title":"Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF1alpha","volume":"271","author":"Li","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.03.008_bb0300","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11427-007-0050-0","article-title":"Differential gene expression of phosphoglyceric kinase (PGK) and hypoxic adaptation in chicken","volume":"50","author":"Wang","year":"2007","journal-title":"Sci. China C Life Sci."},{"key":"10.1016\/j.molmed.2025.03.008_bb0305","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1124\/mol.106.033472","article-title":"The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine","volume":"72","author":"Lam","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0310","article-title":"Novel insights into plasma biomarker candidates in patients with chronic mountain sickness based on proteomics","volume":"41","author":"Zhang","year":"2021","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.molmed.2025.03.008_bb0315","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3390\/biom13101471","article-title":"Newborns with favourable outcomes after perinatal asphyxia have upregulated glucose metabolism-related proteins in plasma","volume":"13","author":"Yip","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.molmed.2025.03.008_bb0320","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12964-024-01757-w","article-title":"Novel energy optimizer, meldonium, rapidly restores acute hypobaric hypoxia-induced brain injury by targeting phosphoglycerate kinase 1","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.molmed.2025.03.008_bb0325","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.molcel.2016.02.009","article-title":"Mitochondria-translocated PGK1 functions as a protein kinase to coordinate glycolysis and the TCA cycle in tumorigenesis","volume":"61","author":"Li","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molmed.2025.03.008_bb0330","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12035-024-04170-z","article-title":"PGK1 is involved in the HIF-1 signaling pathway as a hub gene for ferroptosis after traumatic brain injury","volume":"62","author":"Wang","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2024.149069","article-title":"HIF1A overexpression caused by etomidate activates PGK1-induced oxidative stress in postoperative cognitive dysfunction","volume":"1841","author":"Lu","year":"2024","journal-title":"Brain Res."},{"key":"10.1016\/j.molmed.2025.03.008_bb0340","doi-asserted-by":"crossref","first-page":"8886","DOI":"10.18632\/aging.204343","article-title":"Phosphoglycerate kinase 1 protects against ischemic damage in the gerbil hippocampus","volume":"14","author":"Hahn","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.molmed.2025.03.008_bb0345","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nchembio.1657","article-title":"Terazosin activates Pgk1 and Hsp90 to promote stress resistance","volume":"11","author":"Chen","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0350","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2318956121","article-title":"A model for stimulation of enzyme activity by a competitive inhibitor based on the interaction of terazosin and phosphoglycerate kinase 1","volume":"121","author":"Riley","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2025.03.008_bb0355","article-title":"Terazosin analogs targeting Pgk1 as neuroprotective agents: design, synthesis, and evaluation","volume":"10","author":"Wang","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.molmed.2025.03.008_bb0360","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41598-020-80011-y","article-title":"The effects of meldonium on the acute ischemia\/reperfusion liver injury in rats","volume":"11","author":"Durasevic","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2025.03.008_bb0365","article-title":"Meldonium ameliorates hypoxia-induced lung injury and oxidative stress by regulating platelet-type phosphofructokinase-mediated glycolysis","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0370","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0014-2999(97)81947-4","article-title":"Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo","volume":"338","author":"Calzi","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.molmed.2025.03.008_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.877706","article-title":"The discovery of novel PGK1 activators as apoptotic inhibiting and neuroprotective agents","volume":"13","author":"Qiang","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425000590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425000590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T13:47:48Z","timestamp":1768744068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491425000590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1471491425000590"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2025.03.008","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphoglycerate kinase 1 as a therapeutic target in neurological disease","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2025.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}